### **Appendix 4G**

## Key to Disclosures Corporate Governance Council Principles and Recommendations

Name of entity					
MGC F	MGC PHARMACEUTICALS LTD				
ABN/AI	RBN		Financial year ended:		
30 116 800 269			30 June 2021		
Our corporate governance statement¹ for the period above can be found at:²			ound at: <sup>2</sup>		
	These pages of our annual report:				
$\boxtimes$	This URL on our website:	https://mgcpharma.com.au/invest	or-centre/corporate-governance/		
The Corporate Governance Statement is accurate and up to date as at 30 September 2021 and has been approved by the board.					
The annexure includes a key to where our corporate governance disclosures can be located.3					
Date:	30 September 2021				
	of authorised officer rising lodgement:	David Lim			

Listing Rule 4.10.3 requires an entity that is included in the official list as an ASX Listing to include in its annual report either a corporate governance statement that meets the requirements of that rule or the URL of the page on its website where such a statement is located. The corporate governance statement must disclose the extent to which the entity has followed the recommendations set by the ASX Corporate Governance Council during the reporting period. If the entity has not followed a recommendation for any part of the reporting period, its corporate governance statement must separately identify that recommendation and the period during which it was not followed and state its reasons for not following the recommendation and what (if any) alternative governance practices it adopted in lieu of the recommendation during that period.

Under Listing Rule 4.7.4, if an entity chooses to include its corporate governance statement on its website rather than in its annual report, it must lodge a copy of the corporate governance statement with ASX at the same time as it lodges its annual report with ASX. The corporate governance statement must be current as at the effective date specified in that statement for the purposes of Listing Rule 4.10.3.

Under Listing Rule 4.7.3, an entity must also lodge with ASX a completed Appendix 4G at the same time as it lodges its annual report with ASX. The Appendix 4G serves a dual purpose. It acts as a key designed to assist readers to locate the governance disclosures made by a listed entity under Listing Rule 4.10.3 and under the ASX Corporate Governance Council's recommendations. It also acts as a verification tool for listed entities to confirm that they have met the disclosure requirements of Listing Rule 4.10.3.

The Appendix 4G is not a substitute for, and is not to be confused with, the entity's corporate governance statement. They serve different purposes and an entity must produce each of them separately.

See notes 4 and 5 below for further instructions on how to complete this form.

<sup>&</sup>lt;sup>1</sup> "Corporate governance statement" is defined in Listing Rule 19.12 to mean the statement referred to in Listing Rule 4.10.3 which discloses the extent to which an entity has followed the recommendations set by the ASX Corporate Governance Council during a particular reporting period.

<sup>&</sup>lt;sup>2</sup> Tick whichever option is correct and then complete the page number(s) of the annual report, or the URL of the web page, where your corporate governance statement can be found. You can, if you wish, delete the option which is not applicable.

<sup>&</sup>lt;sup>3</sup> Throughout this form, where you are given two or more options to select, you can, if you wish, delete any option which is not applicable and just retain the option that is applicable. If you select an option that includes "OR" at the end of the selection and you delete the other options, you can also, if you wish, delete the "OR" at the end of the selection.

#### ANNEXURE - KEY TO CORPORATE GOVERNANCE DISCLOSURES

Corpo	rate Governance Council recommendation	Where a box below is ticked, <sup>4</sup> we have followed the recommendation in <u>full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
PRINC	IPLE 1 – LAY SOLID FOUNDATIONS FOR MANAGEMENT AND O	/ERSIGHT	
1.1	A listed entity should have and disclose a board charter setting out:     (a) the respective roles and responsibilities of its board and management; and     (b) those matters expressly reserved to the board and those delegated to management.	and we have disclosed a copy of our board charter at: https://mgcpharma.com.au/investor-centre/corporate-governance/	set out in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
1.2	A listed entity should:     (a) undertake appropriate checks before appointing a director or senior executive or putting someone forward for election as a director; and     (b) provide security holders with all material information in its possession relevant to a decision on whether or not to elect or re-elect a director.		□ set out in our Corporate Governance Statement <u>OR</u> □ we are an externally managed entity and this recommendation is therefore not applicable
1.3	A listed entity should have a written agreement with each director and senior executive setting out the terms of their appointment.		□ set out in our Corporate Governance Statement <u>OR</u> we are an externally managed entity and this recommendation is therefore not applicable
1.4	The company secretary of a listed entity should be accountable directly to the board, through the chair, on all matters to do with the proper functioning of the board.		set out in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable

<sup>&</sup>lt;sup>4</sup> Tick the box in this column only if you have followed the relevant recommendation in <u>full</u> for the <u>whole</u> of the period above. Where the recommendation has a disclosure obligation attached, you must insert the location where that disclosure has been made, where indicated by the line with "insert location" underneath. If the disclosure in question has been made in your corporate governance statement, you need only insert "our corporate governance statement". If the disclosure has been made in your annual report, you should insert the page number(s) of your annual report (eg "pages 10-12 of our annual report"). If the disclosure has been made on your website, you should insert the URL of the web page where the disclosure has been made or can be accessed (eg "www.entityname.com.au/corporate governance/charters/").

<sup>&</sup>lt;sup>5</sup> If you have followed all of the Council's recommendations in full for the whole of the period above, you can, if you wish, delete this column from the form and re-format it.

Corporate Governance Council recommendation		Where a box below is ticked, <sup>4</sup> we have followed the recommendation <u>in full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: <sup>5</sup>
1.5	A listed entity should:  (a) have and disclose a diversity policy;  (b) through its board or a committee of the board set measurable objectives for achieving gender diversity in the composition of its board, senior executives and workforce generally; and  (c) disclose in relation to each reporting period:  (1) the measurable objectives set for that period to achieve gender diversity;  (2) the entity's progress towards achieving those objectives; and  (3) either:  (A) the respective proportions of men and women on the board, in senior executive positions and across the whole workforce (including how the entity has defined "senior executive" for these purposes); or  (B) if the entity is a "relevant employer" under the Workplace Gender Equality Act, the entity's most recent "Gender Equality Indicators", as defined in and published under that Act.  If the entity was in the S&P / ASX 300 Index at the commencement of the reporting period, the measurable objective for achieving gender diversity in the composition of its board should be to have not less than 30% of its directors of each gender within a specified period.	and we have disclosed a copy of our diversity policy at:  [insert location] and we have disclosed the information referred to in paragraph (c) at:  [insert location] and if we were included in the S&P / ASX 300 Index at the commencement of the reporting period our measurable objective for achieving gender diversity in the composition of its board of not less than 30% of its directors of each gender within a specified period.	set out in our Corporate Governance Statement OR  we are an externally managed entity and this recommendation is therefore not applicable
1.6	A listed entity should:     (a) have and disclose a process for periodically evaluating the performance of the board, its committees and individual directors; and     (b) disclose for each reporting period whether a performance evaluation has been undertaken in accordance with that process during or in respect of that period.	and we have disclosed the evaluation process referred to in paragraph (a) at:  https://mgcpharma.com.au/investor-centre/corporate-governance/ and whether a performance evaluation was undertaken for the reporting period in accordance with that process at:  https://mgcpharma.com.au/investor-centre/corporate-governance/	<ul> <li>□ set out in our Corporate Governance Statement <u>OR</u></li> <li>□ we are an externally managed entity and this recommendation is therefore not applicable</li> </ul>

Corporate Governance Council recommendation		Where a box below is ticked, <sup>4</sup> we have followed the recommendation in <u>full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
1.7	A listed entity should:     (a) have and disclose a process for evaluating the performance of its senior executives at least once every reporting period; and     (b) disclose for each reporting period whether a performance evaluation has been undertaken in accordance with that process during or in respect of that period.	and we have disclosed the evaluation process referred to in paragraph (a) at:  https://mgcpharma.com.au/investor-centre/corporate-governance/ and whether a performance evaluation was undertaken for the reporting period in accordance with that process at:  https://mgcpharma.com.au/investor-centre/corporate-governance/	<ul> <li>□ set out in our Corporate Governance Statement <u>OR</u></li> <li>□ we are an externally managed entity and this recommendation is therefore not applicable</li> </ul>

Corpora	ate Governance Council recommendation	Where a box below is ticked, <sup>4</sup> we have followed the recommendation in <u>full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: <sup>5</sup>
PRINCI	PLE 2 - STRUCTURE THE BOARD TO BE EFFECTIVE AND ADD	VALUE	
2.1	The board of a listed entity should:  (a) have a nomination committee which:  (1) has at least three members, a majority of whom are independent directors; and  (2) is chaired by an independent director, and disclose:  (3) the charter of the committee;  (4) the members of the committee; and  (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or  (b) if it does not have a nomination committee, disclose that fact and the processes it employs to address board succession issues and to ensure that the board has the appropriate balance of skills, knowledge, experience, independence and diversity to enable it to discharge its duties and responsibilities effectively.	and we have disclosed a copy of the charter of the committee at: https://mgcpharma.com.au/investor-centre/corporate-governance/ and the information referred to in paragraphs (4) and (5) is available within the Annual Report at: https://mgcpharma.com.au/investor-centre/financial-reports/	set out in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
2.2	A listed entity should have and disclose a board skills matrix setting out the mix of skills that the board currently has or is looking to achieve in its membership.	and we have disclosed our board skills matrix at:  https://mgcpharma.com.au/investor-centre/corporate-governance/	<ul> <li>□ set out in our Corporate Governance Statement <u>OR</u></li> <li>□ we are an externally managed entity and this recommendation is therefore not applicable</li> </ul>

Corporate Governance Council recommendation		Where a box below is ticked, <sup>4</sup> we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: <sup>5</sup>
2.3	A listed entity should disclose:  (a) the names of the directors considered by the board to be independent directors;  (b) if a director has an interest, position, affiliation or relationship of the type described in Box 2.3 but the board is of the opinion that it does not compromise the independence of the director, the nature of the interest, position or relationship in question and an explanation of why the board is of that opinion; and  (c) the length of service of each director.	and we have disclosed the names of the directors considered by the board to be independent directors at:  https://mgcpharma.com.au/investor-centre/corporate-governance/  and, where applicable, the information referred to in paragraph (b) at:  https://mgcpharma.com.au/investor-centre/corporate-governance/  and the length of service of each director is disclosed in the Annual Report a copy of which can be found at:  https://mgcpharma.com.au/investor-centre/financial-reports/	set out in our Corporate Governance Statement
2.4	A majority of the board of a listed entity should be independent directors.		<ul> <li>         ⊠ set out in our Corporate Governance Statement <u>OR</u> </li> <li>         □ we are an externally managed entity and this recommendation is therefore not applicable     </li> </ul>
2.5	The chair of the board of a listed entity should be an independent director and, in particular, should not be the same person as the CEO of the entity.		<ul> <li>         ⊠ set out in our Corporate Governance Statement <u>OR</u> </li> <li>         □ we are an externally managed entity and this recommendation is therefore not applicable     </li> </ul>
2.6	A listed entity should have a program for inducting new directors and for periodically reviewing whether there is a need for existing directors to undertake professional development to maintain the skills and knowledge needed to perform their role as directors effectively.		□ set out in our Corporate Governance Statement <u>OR</u> □ we are an externally managed entity and this recommendation is therefore not applicable

Corpor	ate Governance Council recommendation	Where a box below is ticked, <sup>4</sup> we have followed the recommendation in <u>full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
PRINCI	PLE 3 – INSTIL A CULTURE OF ACTING LAWFULLY, ETHICALL	Y AND RESPONSIBLY	
3.1	A listed entity should articulate and disclose its values.	and we have disclosed our values at: https://mgcpharma.com.au/investor-centre/corporate-governance/	□ set out in our Corporate Governance Statement
3.2	A listed entity should:     (a) have and disclose a code of conduct for its directors, senior executives and employees; and     (b) ensure that the board or a committee of the board is informed of any material breaches of that code.	and we have disclosed our code of conduct at: https://mgcpharma.com.au/investor-centre/corporate-governance/	□ set out in our Corporate Governance Statement
3.3	A listed entity should:     (a) have and disclose a whistleblower policy; and     (b) ensure that the board or a committee of the board is informed of any material incidents reported under that policy.	and we have disclosed our whistleblower policy at: https://mgcpharma.com.au/investor-centre/corporate-governance/	□ set out in our Corporate Governance Statement
3.4	A listed entity should:  (a) have and disclose an anti-bribery and corruption policy; and  (b) ensure that the board or committee of the board is informed of any material breaches of that policy.	and we have disclosed our anti-bribery and corruption policy at: https://mgcpharma.com.au/investor-centre/corporate-governance/	□ set out in our Corporate Governance Statement

Corpora	te Governance Council recommendation	Where a box below is ticked, <sup>4</sup> we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: <sup>5</sup>
PRINCIP	LE 4 – SAFEGUARD THE INTEGRITY OF CORPORATE REPOR	TS	
4.1	The board of a listed entity should:  (a) have an audit committee which:  (1) has at least three members, all of whom are non-executive directors and a majority of whom are independent directors; and  (2) is chaired by an independent director, who is not the chair of the board,  and disclose:  (3) the charter of the committee;  (4) the relevant qualifications and experience of the members of the committee; and  (5) in relation to each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or  (b) if it does not have an audit committee, disclose that fact and the processes it employs that independently verify and safeguard the integrity of its corporate reporting, including the processes for the appointment and removal of the external auditor and the rotation of the audit engagement partner.	[If the entity complies with paragraph (a):] and we have disclosed a copy of the charter of the committee at:  [insert location] and the information referred to in paragraphs (4) and (5) at:  [insert location] [If the entity complies with paragraph (b):] and we have disclosed the fact that we do not have an audit committee and the processes we employ that independently verify and safeguard the integrity of our corporate reporting, including the processes for the appointment and removal of the external auditor and the rotation of the audit engagement partner at:  [insert location]	
4.2	The board of a listed entity should, before it approves the entity's financial statements for a financial period, receive from its CEO and CFO a declaration that, in their opinion, the financial records of the entity have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the financial position and performance of the entity and that the opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.		□ set out in our Corporate Governance Statement
4.3	A listed entity should disclose its process to verify the integrity of any periodic corporate report it releases to the market that is not audited or reviewed by an external auditor.		□ set out in our Corporate Governance Statement

		Where a box below is ticked, <sup>4</sup> we have followed the recommendation in full for the whole of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5		
PRINCIP	LE 5 – MAKE TIMELY AND BALANCED DISCLOSURE				
5.1	A listed entity should have and disclose a written policy for complying with its continuous disclosure obligations under listing rule 3.1.	and we have disclosed our continuous disclosure compliance policy at: https://mgcpharma.com.au/investor-centre/corporate-governance/	□ set out in our Corporate Governance Statement		
5.2	A listed entity should ensure that its board receives copies of all material market announcements promptly after they have been made.		□ set out in our Corporate Governance Statement		
5.3	A listed entity that gives a new and substantive investor or analyst presentation should release a copy of the presentation materials on the ASX Market Announcements Platform ahead of the presentation.		□ set out in our Corporate Governance Statement		
PRINCIP	PRINCIPLE 6 – RESPECT THE RIGHTS OF SECURITY HOLDERS				
6.1	A listed entity should provide information about itself and its governance to investors via its website.	and we have disclosed information about us and our governance on our website at: https://mgcpharma.com.au/investor-centre/corporate-governance/	□ set out in our Corporate Governance Statement		
6.2	A listed entity should have an investor relations program that facilitates effective two-way communication with investors.		□ set out in our Corporate Governance Statement		
6.3	A listed entity should disclose how it facilitates and encourages participation at meetings of security holders.	and we have disclosed how we facilitate and encourage participation at meetings of security holders at:  https://mgcpharma.com.au/investor-centre/corporate-governance/	□ set out in our Corporate Governance Statement		
6.4	A listed entity should ensure that all substantive resolutions at a meeting of security holders are decided by a poll rather than by a show of hands.		□ set out in our Corporate Governance Statement		

Corporate Governance Council recommendation		Where a box below is ticked, <sup>4</sup> we have followed the recommendation <u>in full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are: <sup>5</sup>
6.5	A listed entity should give security holders the option to receive communications from, and send communications to, the entity and its security registry electronically.		□ set out in our Corporate Governance Statement
PRINCIP	LE 7 – RECOGNISE AND MANAGE RISK		
7.1	The board of a listed entity should:  (a) have a committee or committees to oversee risk, each of which:  (1) has at least three members, a majority of whom are independent directors; and  (2) is chaired by an independent director, and disclose:  (3) the charter of the committee;  (4) the members of the committee; and  (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or  (b) if it does not have a risk committee or committees that satisfy (a) above, disclose that fact and the processes it employs for overseeing the entity's risk management framework.	and we have disclosed a copy of the charter of the committee at: https://mgcpharma.com.au/investor-centre/corporate-governance/ and the information referred to in paragraphs (4) and (5) at: https://mgcpharma.com.au/investor-centre/financial-reports/	set out in our Corporate Governance Statement
7.2	The board or a committee of the board should:  (a) review the entity's risk management framework at least annually to satisfy itself that it continues to be sound and that the entity is operating with due regard to the risk appetite set by the board; and  (b) disclose, in relation to each reporting period, whether such a review has taken place.	and we have disclosed whether a review of the entity's risk management framework was undertaken during the reporting period at:  https://mgcpharma.com.au/investor-centre/corporate-governance/	□ set out in our Corporate Governance Statement

		Where a box below is ticked, <sup>4</sup> we have followed the recommendation in <u>full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
PRINCIP	LE 8 – REMUNERATE FAIRLY AND RESPONSIBLY		
8.1	The board of a listed entity should:  (a) have a remuneration committee which:  (1) has at least three members, a majority of whom are independent directors; and  (2) is chaired by an independent director, and disclose:  (3) the charter of the committee;  (4) the members of the committee; and  (5) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or  (b) if it does not have a remuneration committee, disclose that fact and the processes it employs for setting the level and composition of remuneration for directors and senior executives and ensuring that such remuneration is appropriate and not excessive.	and we have disclosed a copy of the charter of the committee at: https://mgcpharma.com.au/investor-centre/corporate-governance/ and the information referred to in paragraphs (4) and (5) at: https://mgcpharma.com.au/investor-centre/financial-reports/	set out in our Corporate Governance Statement OR we are an externally managed entity and this recommendation is therefore not applicable
8.2	A listed entity should separately disclose its policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives.	and we have disclosed separately our remuneration policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives at:  https://mgcpharma.com.au/investor-centre/financial-reports/	□ set out in our Corporate Governance Statement <u>OR</u> □ we are an externally managed entity and this recommendation is therefore not applicable
8.3	A listed entity which has an equity-based remuneration scheme should:     (a) have a policy on whether participants are permitted to enter into transactions (whether through the use of derivatives or otherwise) which limit the economic risk of participating in the scheme; and     (b) disclose that policy or a summary of it.	and we have disclosed our policy on this issue or a summary of it at: https://mgcpharma.com.au/investor-centre/financial-reports/	<ul> <li>□ set out in our Corporate Governance Statement <u>OR</u></li> <li>□ we do not have an equity-based remuneration scheme and this recommendation is therefore not applicable <u>OR</u></li> <li>□ we are an externally managed entity and this recommendation is therefore not applicable</li> </ul>

Corporate Governance Council recommendation		Where a box below is ticked, <sup>4</sup> we have followed the recommendation in <u>full</u> for the <u>whole</u> of the period above. We have disclosed this in our Corporate Governance Statement:	Where a box below is ticked, we have NOT followed the recommendation in full for the whole of the period above. Our reasons for not doing so are:5
ADDITIO	NAL RECOMMENDATIONS THAT APPLY ONLY IN CERTAIN CA	ASES	
9.1	A listed entity with a director who does not speak the language in which board or security holder meetings are held or key corporate documents are written should disclose the processes it has in place to ensure the director understands and can contribute to the discussions at those meetings and understands and can discharge their obligations in relation to those documents.	and we have disclosed information about the processes in place at:	<ul> <li>□ set out in our Corporate Governance Statement <u>OR</u></li> <li>☑ we do not have a director in this position and this recommendation is therefore not applicable <u>OR</u></li> <li>□ we are an externally managed entity and this recommendation is therefore not applicable</li> </ul>
9.2	A listed entity established outside Australia should ensure that meetings of security holders are held at a reasonable place and time.		<ul> <li>□ set out in our Corporate Governance Statement <u>OR</u></li> <li>☑ we are established in Australia and this recommendation is therefore not applicable <u>OR</u></li> <li>□ we are an externally managed entity and this recommendation is therefore not applicable</li> </ul>
9.3	A listed entity established outside Australia, and an externally managed listed entity that has an AGM, should ensure that its external auditor attends its AGM and is available to answer questions from security holders relevant to the audit.		□ set out in our Corporate Governance Statement <u>OR</u> we are established in Australia and not an externally managed listed entity and this recommendation is therefore not applicable      we are an externally managed entity that does not hold an AGM and this recommendation is therefore not applicable



# MGC PHARMACEUTICALS LTD ACN 116 800 269 (Company)

#### CORPORATE GOVERNANCE STATEMENT FOR THE FINANCIAL YEAR ENDING 2021

This Corporate Governance Statement is current as at 30 September 2021 and has been approved by the Board of the Company on that date.

This Corporate Governance Statement discloses the extent to which the Company has, during the financial year ending 30 June 2021, followed the recommendations set by the ASX Corporate Governance Council in its publication Corporate Governance Principles and Recommendations – 4<sup>th</sup> Edition (**Recommendations**). The Recommendations are not mandatory, however the Recommendations that have not been followed for any part of the reporting period have been identified and reasons provided for not following them along with what (if any) alternative governance practices were adopted in lieu of the recommendation during that period.

The Company has adopted a Corporate Governance Plan which provides the written terms of reference for the Company's corporate governance duties.

The Company's Corporate Governance Plan is available on the Company's website at www.mgcpharma.com.au

RECOM	MENDATIONS (4 <sup>TH</sup> EDITION)	COMPLY	EXPLANATION
Principl	e 1: Lay solid foundations for management and oversight		
Recomm (a)	A listed entity should have and disclose a board charter which sets out the respective roles and responsibilities of the Board, the Chair and management, and includes a description of those matters expressly reserved to the Board and those delegated to management.	YES	The Company has adopted a Board Charter that sets out the specific roles and responsibilities of the Board, the Chair and management and includes a description of those matters expressly reserved to the Board and those delegated to management.  The Board Charter sets out the specific responsibilities of the Board, requirements as to the Board's composition, the roles and responsibilities of the Chairman and Company Secretary, the establishment, operation and management of Board Committees, Directors' access to Company records and information, details of the Board's relationship with management, details of the Board's performance review and details of the Board's disclosure policy.  A copy of the Company's Board Charter, which is part of the Company's Corporate Governance Plan, is available on the Company's website.

/1310\_2

RECOMMENDATIO	ONS (4 <sup>TH</sup> EDITION)	COMPLY	EXPLANATION
senior ex Director; (b) provide possession	uld: ke appropriate checks before appointing a director or xecutive or putting someone forward for election as a	YES	<ul> <li>(a) The Company has guidelines for the appointment and selection of the Board and senior executives in its Corporate Governance Plan. The Company's Nomination Committee Charter (in the Company's Corporate Governance Plan) requires the Nomination Committee (or, in its absence, the Board) to ensure appropriate checks (including checks in respect of character, experience, education, criminal record and bankruptcy history (as appropriate)) are undertaken before appointing a person, or putting forward to security holders a candidate for election, as a Director. In the event of an unsatisfactory check, a Director is required to submit their resignation.</li> <li>(b) Under the Nomination Committee Charter, all material information relevant to a decision on whether or not to elect or re-elect a Director must be provided to security holders in the Notice of Meeting containing the resolution to elect or re-elect a Director.</li> </ul>
Recommendation 1.3  A listed entity should have a written agreement with each Director and senior executive setting out the terms of their appointment.		PARTIALLY	The Company's Nomination Committee Charter requires the Nomination Committee (or, in its absence, the Board) to ensure that each Director and senior executive is personally a party to a written agreement with the Company which sets out the terms of that Director's or senior executive's appointment.  The Company has had written agreements with each of its Directors and senior executives for the past financial year, other than the CFO and Company Secretary who are engaged through an external consultancy
The Company Secre	Recommendation 1.4  The Company Secretary of a listed entity should be accountable directly to the Board, through the Chair, on all matters to do with the proper functioning of the Board		The Board Charter outlines the roles, responsibility and accountability of the Company Secretary. In accordance with this, the Company Secretary is accountable directly to the Board, through the Chair, on all matters to do with the proper functioning of the Board.
(b) through objective its board		PARTIALLY	<ul> <li>(a) The Company has adopted a Diversity Policy which provides a framework for the Company to establish, achieve and measure diversity objectives, including in respect of gender diversity. The Diversity Policy is available, as part of the Corporate Governance Plan, on the Company's website.</li> <li>(b) The Diversity Policy allows the Board to set measurable gender diversity objectives and the Company's progress in achieving them.</li> </ul>

RECOM	1MENDATI	ONS (4 <sup>TH</sup> E	DITION)	COMPLY			EXPLANATION	
	(ii) (iii)		the respective proportions of men and women on the Board, in senior executive positions and across the whole workforce (including how the entity has defined "senior executive" for these purposes); or if the entity is a "relevant employer" under the Workplace Gender Equality Act, the		f r r v a The Comp and wom	inancial year, because need to appoint any new nature of the Company's riew that the existing Diand experience to carry any as at 30 June 2021 en on the Board, in second are as follows:	the Board did not antic v Directors or senior exect s existing and proposed a frectors and senior execu- out the Company's plans had the following respec- enior executive positions	ipate there would be a utives due to the limited ctivities and the Board's tives have sufficient skill tive proportions of men and across the whole
			entity's most recent "Gender Equality			Board	Senior Executives	Whole Organisation
			Indicators", as defined in the Workplace Gender Equality Act.		Men Women	100%	73%	14% 86%
reporti in the d directo	If the entity was in the S&P / ASX 300 Index at the commencement of the reporting period, the measurable objective for achieving gender diversity in the composition of its board should be to have not less than 30% of its directors of each gender within a specified period.							
11000111	mendation			YES	(a) The Company's Nomination Committee (or, in its absence, the Board) is responsible for evaluating the performance of the Board, its committees			
(a)	A listed entity should:  (a) have and disclose a process for periodically evaluating the performance of the Board, its committees and individual Directors; and			ā ā	ind individual Directors in independent advisor	on an annual basis. It m The process for this is s Plan, which is availab	ay do so with the aid of et out in the Company's	
(b)	evaluat	tion has l	n reporting period whether a performance been undertaken in accordance with that in respect of that period.		t t	lisclose whether or not he relevant reporting performance evaluation	ate Governance Plan re performance evaluations g period. The Compan is in respect of the Board for the past financial yea	were conducted during y has not completed , its committees (if any)
	Recommendation 1.7		YES	, ,		tion Committee (or, in it ing the performance of		
(a)		nd disclose	e a process for evaluating the performance of ves at least once every reporting period; and		e ( r s	executives on an annual or, in its absence, the emuneration of the Colonion executive, for the	basis. The Company's Re he Board) is responsik mpany's senior executive ese purposes, means key rations Act) other than a	emuneration Committee ole for evaluating the es on an annual basis. A management personnel

RECON	IMENDATIONS (4 <sup>TH</sup> EDITION)	COMPLY	EXPLANATION
(b)	disclose for each reporting period whether a performance evaluation has been undertaken in accordance with that process during or in respect of that period.		The applicable processes for these evaluations can be found in the Company's Corporate Governance Plan, which is available on the Company's website.
			(b) The Company has completed performance evaluations in respect of the senior executives for the past financial year in accordance with the applicable processes.
Princip	le 2: Structure the Board to be effective and add value		
	mendation 2.1  ard of a listed entity should:    have a nomination committee which:    (i) has at least three members, a majority of whom are independent Directors; and    (ii) is chaired by an independent Director,    and disclose:    (iii) the charter of the committee;    (iv) the members of the committee; and    (v) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or    if it does not have a nomination committee, disclose that fact and the processes it employs to address Board succession issues and to ensure that the Board has the appropriate balance of skills, knowledge, experience, independence and diversity to	YES	<ul> <li>(a) The Company had a Nomination Committee for the past financial year. The Company's Nomination Committee Charter provides for the creation of a Nomination Committee (if it is considered it will benefit the Company), with at least three members, a majority of whom are independent Directors, and which must be chaired by an independent Director. The members of the Nomination Committee, the number of times the committee met during the last financial year, and the individual attendances of the members, are disclosed in the Annual Report.  The relevant qualifications and experience of the members of the committee is set out in the Annual Report, along with the relevant attendances at meetings.</li> <li>(b) The Company had a Nomination Committee for the past financial year.</li> </ul>
Pasam	enable it to discharge its duties and responsibilities effectively.	VEC	Under the Namination Committee Charter (in the Company's Cornerate
A liste	mendation 2.2 If entity should have and disclose a Board skills matrix setting out of skills that the Board currently has or is looking to achieve in its ership.	YES	Under the Nomination Committee Charter (in the Company's Corporate Governance Plan), the Nomination Committee (or, in its absence, the Board) is required to prepare a Board skills matrix setting out the mix of skills that the Board currently has (or is looking to achieve) and to review this at least annually against the Company's Board skills matrix to ensure the appropriate mix of skills to discharge its obligations effectively and to add value and to ensure the Board has the ability to deal with new and emerging business and governance issues.

RECON	MMENDATIONS (4 <sup>TH</sup> EDITION)	COMPLY	EXPLANATION
			The Company has, for the past financial year, had a Board skill matrix setting out the mix of skills and diversity that the Board currently has or is looking to achieve in its membership. A copy is available on the Company's website.
			The Board Charter requires the disclosure of each Board member's qualifications and expertise. Full details as to each Director and senior executive's relevant skills and experience are available in the Company's Annual Report.
	mendation 2.3 dentity should disclose: the names of the Directors considered by the Board to be independent Directors; if a Director has an interest, position or relationship of the type described in Box 2.3 of the ASX Corporate Governance Principles and Recommendations (4th Edition), but the Board is of the opinion that it does not compromise the independence of the Director, the nature of the interest, position or relationship in question and an explanation of why the Board is of that opinion; and	YES	<ul> <li>(a) The Board Charter requires the disclosure of the names of Directors considered by the Board to be independent. The Board considers the following Directors are independent: Stephen Parker, Ross Walker and Evan Hayes.</li> <li>(b) On 12 August 2021 the shareholders of the Company agreed to grant the directors Performance Rights over shares of the Company which have as Vesting Conditions, continued tenure as a director and share price targets. The board doesn't believe that the Independence of the above directors is materially compromised by the grant of these securities.</li> <li>(c) The Company's Annual Report discloses the length of service of each Director, as at the end of each financial year.</li> </ul>
(c)	the length of service of each Director	NO	
A majo	Recommendation 2.4  A majority of the Board of a listed entity should be independent Directors.		The Company's Board Charter requires that, where practical, the majority of the Board should be independent.  There was not an independent majority of the Board for all of the past financial year.  The Board did not consider an independent majority of the Board was appropriate for the past financial year given the Company considers at least two (2) Directors need to be executive Directors for the Company to be effectively managed.  The Board currently comprises a total of 6 directors, of whom 3 are considered to be independent. As such, independent directors currently comprise half of the Board.
The Ch	mendation 2.5 air of the Board of a listed entity should be an independent Director particular, should not be the same person as the CEO of the entity.	PARTIALLY	The Board Charter provides that, where practical, the Chair of the Board should be an independent Director and should not be the CEO/Managing Director.  The Chair of the Company during the past financial year was not an independent Director and was not the CEO/Managing Director.  The Board did not have an independent Chair because it was not feasible due to the company's current size and Board structure.

RECON	RECOMMENDATIONS (4 <sup>TH</sup> EDITION)		EXPLANATION
A listed	Recommendation 2.6  A listed entity should have a program for inducting new Directors and for periodically reviewing whether there is a need for existing directors to undertake professional development to maintain the skills and knowledge needed to perform their role as Directors effectively.		In accordance with the Company's Board Charter, the Nominations Committee (or, in its absence, the Board) is responsible for the approval and review of induction and continuing professional development programs and procedures for Directors to ensure that they can effectively discharge their responsibilities.
Princip	le 3: Instil a culture of acting lawfully, ethically and responsibly		
Recommendation 3.1 A listed entity should articulate and disclose its values.		YES	(a) The Company and its subsidiary companies (if any) are committed to conducting all of its business activities fairly, honestly with a high level of integrity, and in compliance with all applicable laws, rules and regulations. The Board, management and employees are dedicated to high ethical standards and recognise and support the Company's commitment to compliance with these standards.
			(b) The Company's values are set out in its Code of Conduct (which forms part of the Corporate Governance Plan) and are available on the Company's website.
	d entity should:  have and disclose a code of conduct for its Directors, senior executives and employees; and ensure that the Board or a committee of the Board is informed of any material breaches of that code.	YES	<ul> <li>(a) The Company's Corporate Code of Conduct applies to the Company's Directors, senior executives and employees.</li> <li>(b) The Company's Corporate Code of Conduct (which forms part of the Company's Corporate Governance Plan) is available on the Company's website. Any material breaches of the Code of Conduct are reported to the Board or a committee of the Board.</li> </ul>
Recommendation 3.3  A listed entity should:  (a) have and disclose a whistle-blower policy; and  (a) ensure that the Board or a committee of the Board is informed of any material incidents reported under that policy.		YES	The Company's Whistle-blower Protection Policy (which forms part of the Corporate Governance Plan) is available on the Company's website. Any material breaches of the Whistle-blower Protection Policy are to be reported to the Board or a committee of the Board.
Recommendation 3.4  A listed entity should:  (a) have and disclose an anti-bribery and corruption policy; and  (b) ensure that the Board or committee of the Board is informed of any material breaches of that policy.		YES	The Company's Anti-Bribery and Anti-Corruption Policy (which forms part of the Corporate Governance Plan) is available on the Company's website. Any material breaches of the Anti-Bribery and Anti-Corruption Policy are to be reported to the Board or a committee of the Board.

RECON	RECOMMENDATIONS (4 <sup>TH</sup> EDITION)			EXPLANATION	
Princip	le 4: Safe	guard the integrity of corporate reports			
	have a (i)  (ii)  and di (iii) (iv)  (v)  if it do proces the int for the	sted entity should: In audit committee which: In audit committee which: In audit committee which: In audit committee which: In audit committee members, all of whom are non-executive Directors and a majority of whom are independent Directors; and Is chaired by an independent Director, who is not the Chair of the Board, Is close: Ithe charter of the committee; Ithe relevant qualifications and experience of the members of the committee; and In relation to each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or  The ses it employs that independently verify and safeguard tegrity of its corporate reporting, including the processes appointment and removal of the external auditor and tation of the audit engagement partner.	PARTIALLY	<ul> <li>(a) The Company had an Audit and Risk Committee for the past financial The Company's Corporate Governance Plan contains an Audit and Committee Charter that provides for the creation of an Audit and Committee with at least three members, all of whom must be executive Directors, and majority of the Committee must be independent Directors. The Committee must be chaired by an independent Directors on the Chair.</li> <li>The Company complies with all of the above with the exception of heall non-executive directors on the committee, this is due to the size nature of the board and decentralised structure of the Compbusiness operations.</li> <li>The relevant qualifications and experience of the members of committee is set out in the Annual Report, along with the releast attendances at meetings.</li> <li>(b) The Company had an Audit and Risk Committee for the past financial</li> </ul>	I Risk I Risk non- ident ector aving and any's  f the evant
Recommendation 4.2  The Board of a listed entity should, before it approves the entity's financial statements for a financial period, receive from its CEO and CFO a declaration that the financial records of the entity have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the financial position and performance of the entity and that the opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.		YES	The Company's Audit and Risk Committee Charter requires the CEO and CFO none, the person(s) fulfilling those functions) to provide a sign off on these terms for each of its final statements in the past financial year.	erms.	

RECOMMENDATIONS (4 <sup>TH</sup> EDITION)	COMPLY	EXPLANATION
Recommendation 4.3  A listed entity should disclose its process to verify the integrity of any periodic corporate report it releases to the market that is not audited or reviewed by an external auditor.	YES	The Board, before it approves the financial statements for a financial period, receives from the CEO and the CFO/CFO equivalent, a declaration that, in their opinion, the financial records of the entity have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the financial position and performance of the entity and that the opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.
Principle 5: Make timely and balanced disclosure		
Recommendation 5.1 A listed entity should have and disclose a written policy for complying with its continuous disclosure obligations under listing rule 3.1.	YES	<ul> <li>(a) The Company's Corporate Governance Plan details the Company's Continuous Disclosure policy.</li> <li>(b) The Corporate Governance Plan, which incorporates the Continuous Disclosure policy, is available on the Company's website.         https://mgcpharma.com.au/investor-centre/corporate-governance/     </li> </ul>
Recommendation 5.2  A listed entity should ensure that its board receives copies of all material market announcements promptly after they have been made.	YES	Under the Company's Continuous Disclosure Policy (which forms part of the Corporate Governance Plan), all members of the Board receive material market announcements promptly after they have been made.
Recommendation 5.3  A listed entity that gives a new and substantive investor or analyst presentation should release a copy of the presentation materials on the ASX Market Announcements Platform ahead of the presentation.	YES	All substantive investor or analyst presentations were released on the ASX Markets Announcement Platform ahead of such presentations.
Principle 6: Respect the rights of security holders		
Recommendation 6.1  A listed entity should provide information about itself and its governance to investors via its website.	YES	Information about the Company and its governance is available in the Corporate Governance Plan which can be found on the Company's website at: https://mgcpharma.com.au/investor-centre/corporate-governance/
Recommendation 6.2  A listed entity should have an investor relations program that facilitates effective two-way communication with investors.	YES	The Company has adopted a Shareholder Communications Strategy which aims to promote and facilitate effective two-way communication with investors. The Strategy outlines a range of ways in which information is communicated to shareholders and is available on the Company's website as part of the Company's Corporate Governance Plan at:  https://mgcpharma.com.au/investor-centre/corporate-governance/

RECOMMENDATIO	DNS (4 <sup>TH</sup> EDITION)	COMPLY	EXPLANATION
-	<b>6.3</b> should disclose how it facilitates and encourages eetings of security holders.	YES	Shareholders are encouraged to participate at all general meetings and AGMs of the Company. Upon the despatch of any notice of meeting to Shareholders, the Company Secretary shall send out material stating that all Shareholders are encouraged to participate at the meeting.  During the year the Company provided Shareholders with the opportunity to participate in shareholder meetings by live webcasting meetings online.
	<b>6.4</b> uld ensure that all substantive resolutions at a meeting are decided by a poll rather than by a show of hands.	YES	All resolutions at securityholder meetings were decided by a poll rather than a show of hands.
	hould give security holders the option to receive rom, and send communications to, the entity and its	YES	The Shareholder Communication Strategy provides that security holders can register with the Company to receive email notifications when an announcement is made by the Company to the ASX, including the release of the Annual Report, half yearly reports and quarterly reports. Links are made available to the Company's website on which all information provided to the ASX is immediately posted. The Company's website and ASX announcements provide contact details for the Company to allow security holders to communicate with the Company should they have any queries.  Shareholders queries are referred to the Company Secretary at first instance.
Principle 7: Recogn	nise and manage risk		
Recommendation The Board of a liste (a) have a cool (ii)  (iii) and discool (iii)  (iv) (v)	ed entity should: ommittee or committees to oversee risk, each of which: has at least three members, a majority of whom are independent Directors; and is chaired by an independent Director,	YES	(a) The Company had an Audit and Risk Committee for the past financial year. The Company's Corporate Governance Plan contains an Audit and Risk Committee Charter that provides for the creation of an Audit and Risk Committee with at least three members, and majority of the Committee must be independent Directors. The Committee must be chaired by an independent Director who is not the Chair.  A copy of the Corporate Governance Plan is available on the Company's website. The members of the Audit and Risk Committee, the number of times the committee met during the last financial year, and the individual attendances of the members, are disclosed in the Annual Report.

RECON	MMENDATIONS (4 <sup>TH</sup> EDITION)	COMPLY	EXPLANATION
(b)	the individual attendances of the members at those meetings; or  if it does not have a risk committee or committees that satisfy (a) above, disclose that fact and the process it employs for overseeing the entity's risk management framework.		
	pard or a committee of the Board should:  review the entity's risk management framework at least annually to satisfy itself that it continues to be sound and that the entity is operating with due regard to the risk appetite set by the Board; and disclose in relation to each reporting period, whether such a review has taken place.	YES	<ul> <li>(a) The Audit and Risk Committee Charter requires that the Audit and Risk Committee (or, in its absence, the Board) should, at least annually, satisfy itself that the Company's risk management framework continues to be sound and that the Company is operating with due regard to the risk appetite set by the Board.</li> <li>(b) The Company's Audit and Risk Committee has completed a review of the Company's risk management framework in the past financial year.</li> </ul>
	d entity should disclose:  if it has an internal audit function, how the function is structured and what role it performs; or  if it does not have an internal audit function, that fact and the processes it employs for evaluating and continually improving the effectiveness of its governance, risk management and internal control processes.	YES	<ul> <li>(a) The Audit and Risk Committee Charter provides for the Audit and Risk Committee to monitor and periodically review the need for an internal audit function, as well as assessing the performance and objectivity of any internal audit procedures that may be in place.</li> <li>(b) The Company did not have an internal audit function for the past financial year. During the year the Company is subject to a Half-Year financial Review and Full-Year Audit at which time the external auditor undertakes a review of the Company financial internal control functions. Whilst not having an internal audit function the Company undertakes regular checks of such items as cash and inventory, and its EU GMP certified facility is periodically audited by external parties to ensure compliance with registration requirements.</li> </ul>
Recommendation 7.4  A listed entity should disclose whether it has any material exposure to environmental or social risks and, if it does, how it manages or intends to manage those risks.		YES	The Audit and Risk Committee Charter requires the Audit and Risk Committee (or, in its absence, the Board) to assist management to determine whether the Company has any potential or apparent exposure to environmental or social risks and, if it does, put in place management systems, practices and procedures to manage those risks.  The Company's Corporate Governance Plan requires the Company to disclose whether it has any potential or apparent exposure to environmental or social risks and, if it does, put in place management systems, practices and procedures to manage those risk.

RECOM	MENDATI	ONS (4 <sup>TH</sup> EDITION)	COMPLY	EXPLANATION
				Where the Company does not have material exposure to environmental or social risks, report the basis for that determination to the Board, and where appropriate benchmark the Company's environmental or social risk profile against its peers. The Company will disclose this information in its Annual Report.  With the ongoing COVID 19 Pandemic, the Company faces risks associated with the spread of the disease throughout it workforce, and as such has put in place measures to mitigate the risk of exposure to its staff. These include allowing employees to work from home where necessary, and an increased focus on hygiene and preventative measures when advised to do so by the relevant government health offices, The Company has a policy of minimising unnecessary face to face interactions in high risk environments were possible, and utilising technology to facilitate day to day business where possible.
Principle	8: Remu	nerate fairly and responsibly		
The Boar	have a (i) (ii) and dis (iii) (iv) (v)	remuneration committee which:  has at least three members, a majority of whom are independent Directors; and is chaired by an independent Director, close:  the charter of the committee; the members of the committee; and as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or	YES	(a) The Company had a Remuneration Committee for the past financial year. The Company's Corporate Governance Plan contains a Remuneration Committee Charter that provides for the creation of a Remuneration Committee (if it is considered it will benefit the Company), with at least three members, a majority of whom are be independent Directors, and which must be chaired by an independent Director.  The members of the Remuneration Committee, the number of times the committee met during the last financial year, and the individual attendances of the members, are disclosed in the Annual Report.
(b)	and the compose execution	es not have a remuneration committee, disclose that fact the processes it employs for setting the level and sition of remuneration for Directors and senior wes and ensuring that such remuneration is appropriate the excessive.		

RECOMMENDATIONS (4 <sup>TH</sup> EDITION)	COMPLY	EXPLANATION
Recommendation 8.2  A listed entity should separately disclose its policies and practices regarding the remuneration of non-executive Directors and the remuneration of executive Directors and other senior executives.	YES	The Company's Corporate Governance Plan requires the Board to disclose its policies and practices regarding the remuneration of Directors and senior executives, which is disclosed in the remuneration report contained in the Company's Annual Report.
Recommendation 8.3  A listed entity which has an equity-based remuneration scheme should:  (a) have a policy on whether participants are permitted to enter into transactions (whether through the use of derivatives or otherwise) which limit the economic risk of participating in the scheme; and  (b) disclose that policy or a summary of it.	YES	The Company had an equity-based remuneration scheme during the past financial year. The Company did have a policy on whether participants are permitted to enter into transactions (whether through the use of derivatives or otherwise) which limit the economic risk of participating in the scheme. Under the policy directors and officers are prohibited from entering into transactions or arrangements which operate to limit the economic risk of their security holding in the Company without first seeking and obtaining written acknowledgement from the Chair.
Additional recommendations that apply only in certain cases		
Recommendation 9.1  A listed entity with a director who does not speak the language in which board or security holder meetings are held or key corporate documents are written should disclose the processes it has in place to ensure the director understands and can contribute to the discussions at those meetings and understands and can discharge their obligations in relation to those documents.	N/A	
Recommendation 9.2  A listed entity established outside Australia should ensure that meetings of security holders are held at a reasonable place and time.	N/A	
Recommendation 9.3  A listed entity established outside Australia, and an externally managed listed entity that has an AGM, should ensure that its external auditor attends its AGM and is available to answer questions from security holders relevant to the audit.	N/A	